Surgical treatment of an advanced GIST the age of imatinib

Tarn, 2006, The molecular pathogenesis of gastrointestinal stromal tumors, Clin Colorectal Cancer, 6, S7, 10.3816/CCC.2006.s.002

Mazur, 1983, Gastric stromal tumors. Reappraisal of histogenesis, Am J Surg Pathol, 7, 507, 10.1097/00000478-198309000-00001

Demetri, 2007, NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) —up- date of the NCCN clinical practice guidelines, J Natl Compr Canc Netw, 5, S1, 10.6004/jnccn.2010.0116

Thomas, 1995, Gastrointestinal cancer, Cancer, 75, 154, 10.1002/1097-0142(19950101)75:1+<154::AID-CNCR2820751305>3.0.CO;2-Z

Robinson, 2000, Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal, Am J Pathol, 156, 1157, 10.1016/S0002-9440(10)64984-X

Gold JS, DeMatteo RP. Combined surgical and molecular therapy. The gastrointestinal stromal tumor model. Ann Surg 244(2):176–184.

Miettinen, 2003, Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases, Am J Surg Pathol, 27, 625, 10.1097/00000478-200305000-00006

Miettinen, 2000, Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT), Mod Pathol, 13, 1134, 10.1038/modpathol.3880210

DeMatteo, 2000, Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival, Ann Surg, 231, 51, 10.1097/00000658-200001000-00008

Kindblom, 2003

Emory, 1999, Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site, Am J Surg Pathol, 23, 82, 10.1097/00000478-199901000-00009

Tornillo, 2006, An update on molecular genetics of gastrointestinal stromal tumours, J Clin Pathol, 59, 557, 10.1136/jcp.2005.031112

Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577

Corless, 2004, Biology of gastrointestinal stromal tumors, J Clin Oncol, 22, 3813, 10.1200/JCO.2004.05.140

Miettinen, 2006, Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis, Arch Pathol Lab Med, 130, 1466, 10.5858/2006-130-1466-GSTROM

Fletcher JA. Efecto de imatinib sobre la señalización de tirosin quinasa. In: Sarcoma EIS y GIST. ESMO international Symposium. Milán, 2006. El modelo GIST: impacto antitumoral del tratamiento dirigido a la tirosin quinasa: 4–5.

Glivecs (imatinib). Ficha técnica. East Hannover: NovartisPharmaceuticals Corporation; 2007.

Ng, 1992, Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging, Ann Surg, 215, 68, 10.1097/00000658-199201000-00010

Ng, 1992, Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas, Cancer, 69, 1334, 10.1002/1097-0142(19920315)69:6<1334::AID-CNCR2820690606>3.0.CO;2-S

www.gistgolscme.com (acceded January 08)

Artigas-Raventós, 2006, Tumores de la estroma gastrointestinal: nuevos conceptos y estrategias terapéuticas multidisciplinarias médico-quirúrgicas, Cir Esp, 79, 1, 10.1016/S0009-739X(06)70806-5

Joensuu, 2001, Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor, N Engl J Med, 344, 1052, 10.1056/NEJM200104053441404

Tamborini E. Actualizació n sobre los mecanismos de acción del tratamiento dirigido molecular. In: Sarcoma EIS y GIST. ESMO international Symposium. Milán, 2006. Tumores estromales gastrointestinales: una actualización exhaustiva. p. 23–5.

Blanke, 2008, Long-term results from a randomized phase II trial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT, J Clin Oncol, 26, 620, 10.1200/JCO.2007.13.4403

Van Oosterom, 2001, STI 571, an active drug in metastatic Gastro Intestinal Stromal Tumors (GIST), an EORTC Phase I Study, Proc Am Soc Clin Oncol, 20

van Oosterom, 2001, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study, Lancet, 358, 1421, 10.1016/S0140-6736(01)06535-7

Blanke, 2006, Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate, J Clin Oncol, 9528, 10.1200/jco.2006.24.18_suppl.9528

Blanke, 2006, ASCO

Verweij, 2004, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial, Lancet, 364, 1127, 10.1016/S0140-6736(04)17098-0

Benjamin, 2003, Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results, Proc Am Soc Clin Oncol, 22

Rankin, 2004, Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase III Sarcoma Group Study S0033, J Clin Oncol, 9005, 10.1200/jco.2004.22.14_suppl.9005

Wilson, 2005, Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation, Health Technol Assess, 9, 1, 10.3310/hta9250

DeMatteo, 2007, Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?, Ann Surg Oncol, 14, 1, 10.1245/s10434-006-9035-7

Yoon, 2007, Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?, Ann Surg Oncol, 14, 1784, 10.1245/s10434-006-9344-x

Eisenberg, 2004, Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy, Ann Surg Oncol, 11, 465, 10.1245/ASO.2004.09.011

Barnes, 2005, Review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec), Int J Surg, 3, 206, 10.1016/j.ijsu.2005.04.001

Gold, 2007, Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance, Ann Surg Oncol, 14, 1247, 10.1245/s10434-006-9291-6

Katz, 2004, Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor, Anticancer Drugs, 15, 599, 10.1097/01.cad.0000132236.38297.a7

Haller, 2007, Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations, Ann Surg Oncol, 14, 526, 10.1245/s10434-006-9228-0

Bümming, 2003, Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients, Br J Cancer, 89, 460, 10.1038/sj.bjc.6600965

Liu, 2004, Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour, ANZ J Surg, 74, 289, 10.1111/j.1445-2197.2004.02973.x

Loughrey, 2005, Gastrointestinal stromal tumour treated with neoadjuvant imatinib, J Clin Pathol, 58, 779, 10.1136/jcp.2004.023226

Shah, 2005, Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor, Gastrointest Endosc, 61, 625, 10.1016/S0016-5107(04)02642-2

Salazar, 2006, First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy, Gut, 55, 585, 10.1136/gut.2005.086744

Wasserberg, 2007, Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors?, Int J Colorectal Dis, 22, 981, 10.1007/s00384-006-0104-y

Andtbacka, 2007, Surgical resection of gastrointestinal stromal tumors after treatment with imatinib, Ann Surg Oncol, 14, 14, 10.1245/s10434-006-9034-8

Hohenberger, 2006, Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST), J Clin Oncol, 9500, 10.1200/jco.2006.24.18_suppl.9500

Eisenberg, 2009, Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST) – early results of RTOG S0132/ACRIN 6665, J Surg Oncol, 99, 42, 10.1002/jso.21160

Gronchi A. Surgery in advanced/metastatic GIST. In: Gronchi A, Mazzaferro V, directores. Surgery for NET & GIST tumors. An international workshop on surgery and new treatment strategies for neuroendocrine and gastrointestinal stromal tumors. Milán, 2007.

Trent J. A Prospective, randomized, phase II study of preoperative plus postoperative Imatinib Mesylate (Gleevec, formerly STI-571) in patients with primary, recurrent, or metastatic resectable, kit-expressing, gastrointestinal stromal tumor (GIST). [cited January 2008]. Available from: http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/index/ID03-0023

van der Zwan, 2005, Gastrointestinal stromal tumor: 5 years later, Cancer, 104, 1781, 10.1002/cncr.21419

Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol, 21, 4342, 10.1200/JCO.2003.04.190

Debiec-Rychter, 2004, Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer, 40, 689, 10.1016/j.ejca.2003.11.025

Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4

van den Abbeele, 2001, F18-FDG-PET Provides Early Evidence of Biological Response to STI571 in Patients with Malignant Gastrointestinal Stromal Tumors (GIST), Proc Am Soc Clin Oncol, 20

von Mehren, 2006, Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors, Clin Colorectal Cancer, 6, S30, 10.3816/CCC.2006.s.005

Demetri, 2006, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, 368, 1329, 10.1016/S0140-6736(06)69446-4

Judson, 2006, Updated results from a phase III trial of sunitinib in advanced gastrointestinal stromal tumor (gist), Ann Oncol, 162

Eisenberg, 2006, Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials, Clin Colorectal Cancer, 6, S24, 10.3816/CCC.2006.s.004

Antonescu, 2005, Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation, Clin Cancer Res, 11, 4182, 10.1158/1078-0432.CCR-04-2245

Gronchi, 2007, Surgery of residual disease following molecular targeted therapy with imatinib mesylate in advanced/metastatic GIST, Ann Surg, 245, 341, 10.1097/01.sla.0000242710.36384.1b

DeMatteo, 2007, Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor, Ann Surg, 245, 347, 10.1097/01.sla.0000236630.93587.59

Bui, 2006, Do patients with initially resected metastatic GIST benefit from “adjuvant” imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial, J Clin Oncol, 9501, 10.1200/jco.2006.24.18_suppl.9501

Raut, 2006, Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors, J Clin Oncol, 24, 2325, 10.1200/JCO.2005.05.3439

Rutkowski, 2006, Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate, J Surg Oncol, 93, 304, 10.1002/jso.20466

Bauer, 2005, Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib, Int J Cancer, 117, 316, 10.1002/ijc.21164

Sym, 2008, Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs), J Surg Oncol, 98, 27, 10.1002/jso.21065

Schulick, 2007, Effective neoadjuvant therapy prior to metastasectomy: a new paradigm, Ann Surg, 245, 353, 10.1097/01.sla.0000256393.24245.fc

Hohenberger P. Multi-modality therapy. In: GIST Global Opinion Leader Summit (GOLS) 2007. Extending survival with multi-modality approaches in GIST therapy. (e-Newsletter). Ginebra; 2007.

Benjamin, 2006, Management of gastrointestinal stromal tumors in the imatinib era: selected case studies, Oncologist, 11, 9, 10.1634/theoncologist.11-1-9

Jamali, 2007, Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy, Oncologist, 12, 438, 10.1634/theoncologist.12-4-438

Kobayashi, 2006, Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors, Cancer, 107, 2833, 10.1002/cncr.22336

Pawlik, 2006, Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver, Arch Surg, 141, 537, 10.1001/archsurg.141.6.537

Clinical management of GIST. Understanding the new para- digms. An educational newsletter including highlights from the 2003 CTOS annual meeting and Helsinki GIST symposium. Novartis Oncology. April 2004.

Maluccio, 2006, Treatment of metastatic sarcoma to the liver with bland embolization, Cancer, 107, 1617, 10.1002/cncr.22191

Serralta, 2004, Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumors, Eur J Gastroenterol Hepatol, 16, 1237, 10.1097/00042737-200411000-00025

Lang, 2000, Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period, Ann Surg, 231, 500, 10.1097/00000658-200004000-00007

Blay, 2007, Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group, J Clin Oncol, 25, 1107, 10.1200/JCO.2006.09.0183

Demetri, 2004, SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST), J Clin Oncol, 3001, 10.1200/jco.2004.22.14_suppl.3001

NCCN Clinical Practice Guidelines in Oncology™ Soft Tissue Sarcoma [http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf] V.3.2007 GIST. Data accesed: February 2008.

Fiore, 2009, Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST), Eur J Surg Oncol, 10.1016/j.ejso.2008.11.005